Immunotherapy Harnessing Your Natural Killer Cells
Dendritic Cells
Dendritic cells (DC) represent a heterogeneous group of innate immune cells that infiltrate tumors and process and present tumor-derived antigens to T cells. DC plays a critical role in priming anti-tumor T cell immunity and is a major therapeutic target for cancer immunotherapy. Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with critical roles in initiating and regulating innate and adaptive immune responses known as anti-cancer immunotherapy. DC therapy has been spotlighted, given its crucial role in creating anti-tumor T cell immunity for decades. As a result, there has been much interest in improving cancer immunotherapy with many strategies developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs. DC subsets and how the tumor microenvironment shapes these have improved therapies for cancer.
KILLER T CELLS- THE CANCER ASSASSIN
DENDRITIC CELLS “KISS OF DEATH “ TO CANCER